Reported Sunday, Amgen's Repatha Cuts First Major Cardiovascular Event Risk By 29% In High-Risk Diabetes Patients In VESALIUS-CV Subgroup Analysis

Loading news article.

Reported Sunday, Amgen's Repatha Cuts First Major Cardiovascular Event Risk By 29% In High-Risk Diabetes Patients In VESALIUS-CV Subgroup Analysis | WAPE

Reported Sunday, Amgen's Repatha Cuts First Major Cardiovascular Event Risk By 29% In High-Risk Diabetes Patients In VESALIUS-CV Subgroup Analysis

Article summary

Related companies

Comments —